Security
Anzu Special Acquisition Corp I Warrant · ANZUW
ANZUWNASDAQWarrantHistorical · closed Sep 29, 2023CIK 1840877Updated Oct 28, 2026
Name history
Anzu Special Acquisition Corp I · through Sep 29, 2023
Current security for this SEC filerCOCH · NASDAQ
ANZUW price & chart
Historical security
This listing closed Sep 29, 2023. Live provider charts are shown only for current listings.
Current security: COCH
About the company
We are a hearing health company focused on providing innovative medical technologies across the hearing loss spectrum. Our technologies are designed to shift the paradigm within the hearing industry and bring both providers and patients the hearing devices they desire. Founded in 1995, our vision is to create fully implanted hearing devices that leverage the natural ear - not an artificial microphone - to pick up sound. In recent years, we have focused almost exclusively on developing the fully implanted Acclaim® cochlear implant (the “Acclaim CI”), our lead product candidate.
In the news
No coverage from other publishers is available.
Recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Other Events
Items 8.01, 9.01
DEFA14A filing
DEF 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 8,181,000Source | 9,397,000Source | 23,949,000Source | 9,900,000Source | 6,737,000Source | 29,822,000Source | 10,385,000Source | 8,480,000Source | 8,558,000Source | 11,538,000Source | 7,640,000Source | 430,621,346Source |
| Property, Plant and Equipment, NetUSD | 1,116,000Source | 1,197,000Source | 921,000Source | 1,136,000Source | 632,000Source | 962,000Source | 1,220,000Source | 317,000Source | 1,035,000Source | 1,275,000Source | 351,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | — | — | — | — | — | — | 4,218,000Source | 107,773Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 35,000Source | 197,000Source | 49,000Source | 43,000Source | 174,000Source | 31,000Source | 42,000Source | 189,000Source | 34,000Source | 38,000Source | 70,000Source | — |
| Inventory, NetUSD | 1,639,000Source | 1,641,000Source | 1,579,000Source | 1,587,000Source | 1,582,000Source | 1,490,000Source | 1,657,000Source | 1,455,000Source | 1,546,000Source | 1,708,000Source | 1,404,000Source | — |
| Assets, CurrentUSD | 5,757,000Source | 7,136,000Source | 21,917,000Source | 7,513,000Source | 4,996,000Source | 27,682,000Source | 8,312,000Source | 7,730,000Source | 6,279,000Source | 9,384,000Source | 6,825,000Source | 220,422Source |
| Prepaid Expense and Other Assets, CurrentUSD | 508,000Source | 842,000Source | 593,000Source | 576,000Source | 1,466,000Source | 893,000Source | 1,278,000Source | 1,109,000Source | 941,000Source | 1,375,000Source | 957,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 15,712,000Source | 27,926,000Source | 20,255,000Source | 39,759,000Source | 19,124,000Source | 19,270,000Source | 34,609,000Source | 15,893,000Source | 20,325,000Source | 30,380,000Source | 9,402,000Source | 18,788,923Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,000Source | — | 8,000Source | 2,000Source | — | 8,000Source | 2,000Source | — | 3,000Source | — | — | — |
| Additional Paid in CapitalUSD | 298,116,000Source | 259,119,000Source | 329,786,000Source | 268,170,000Source | 257,920,000Source | 329,371,000Source | 266,861,000Source | 257,581,000Source | 301,355,000Source | 266,013,000Source | 255,596,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -305,659,000Source | -277,543,000Source | -326,369,000Source | -297,912,000Source | -270,203,000Source | -319,097,000Source | -290,970,000Source | -264,877,000Source | -313,396,000Source | -284,734,000Source | -257,242,000Source | -17,915,833Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -120,000Source | -121,000Source | -122,000Source | -119,000Source | -120,000Source | -121,000Source | -117,000Source | -119,000Source | -120,000Source | -123,000Source | -118,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | -7,661,000Source | -18,543,000Source | 3,303,000Source | -29,859,000Source | -12,401,000Source | 10,161,000Source | -24,224,000Source | -7,427,000Source | -12,158,000Source | -18,842,000Source | -1,762,000Source | -17,914,770Source |
| Liabilities and EquityUSD | 8,181,000Source | 9,397,000Source | 23,949,000Source | 9,900,000Source | 6,737,000Source | 29,822,000Source | 10,385,000Source | 8,480,000Source | 8,558,000Source | 11,538,000Source | 7,640,000Source | 430,621,346Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,988,000Source | 9,074,000Source | 12,634,000Source | 8,000,000Source | 8,058,000Source | 12,211,000Source | 7,595,000Source | 6,996,000Source | 11,562,000Source | 7,538,000Source | 6,636,000Source | 7,309,756Source |
| Accounts Payable, CurrentUSD | 2,681,000Source | 1,757,000Source | 2,035,000Source | 1,619,000Source | 1,589,000Source | 1,700,000Source | 1,662,000Source | 913,000Source | 2,920,000Source | 1,652,000Source | 1,554,000Source | 1,177,546Source |
| Other Liabilities, NoncurrentUSD | 891,000Source | — | 27,000Source | 891,000Source | — | 27,000Source | 891,000Source | — | 27,000Source | 891,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,864,000Source | 6,854,000Source | 10,032,000Source | 4,696,000Source | 6,004,000Source | 9,653,000Source | 5,057,000Source | 5,621,000Source | 7,639,000Source | 4,416,000Source | 4,613,000Source | 3,945,680Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 433,000Source | — | — |
| Dividends PayableUSD | 2,626,000Source | — | 6,418,000Source | 1,361,000Source | — | 5,128,000Source | — | — | 3,778,000Source | — | — | — |
| Additional Paid in Capital, Common Stock | — | — | — | — | — | — | — | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 19,233,710Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 239,000Source | 160,000Source | 657,000Source | 562,000Source | 1,575,000Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,000Source | 4,000Source | -4,000Source | -32,000Source | 29,000Source | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -44,000Source | -74,000Source | -126,000Source | 380,000Source | 10,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,220,000Source | 10,000Source | 1,385,000Source | -19,000Source | 551,000Source | 558,804Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 2,585,000Source | 5,776,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,061,000Source | -3,725,000Source | -18,201,000Source | -17,949,000Source | -17,654,000Source | -2,657,582Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -6,000Source | -179,000Source | -980,000Source | -153,000Source | 1,115,510Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 6,000Source | 179,000Source | 980,000Source | 153,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 27,574,000Source | 3,554,000Source | 16,633,000Source | 20,198,000Source | 21,845,000Source | 1,500,000Source |
| Dividends paid | — | — | — | — | — | — | — | —Source | —Source | —Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 21,512,000Source | -171,000Source | -1,744,000Source | 1,265,000Source | 4,035,000Source | -42,072Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 3,556,000Source | 4,424,000Source | 19,679,000Source | 5,287,000Source | 25,251,000Source | 5,312,000Source | 3,739,000Source | 5,483,000Source | 4,218,000Source | 107,773Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 11,000Source | 13,000Source | 36,000Source | 41,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -1,000Source | 6,000Source | 3,000Source | -5,000Source | -3,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 44,000Source | 160,000Source | 657,000Source | 562,000Source | 1,575,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 495,000Source | 1,590,000Source | 816,000Source | — | — |
| DepreciationUSD | — | — | 76,000Source | 49,000Source | 74,000Source | 85,000Source | 73,000Source | 61,000Source | 302,000Source | 173,000Source | 133,000Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | 411,000Source | — | — |
| Dividends PayableUSD | — | — | 2,626,000Source | — | 6,418,000Source | 1,361,000Source | 5,128,000Source | — | 3,778,000Source | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 103,000Source | -69,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 27,879,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,442,000Source | 1,690,000Source | 2,029,000Source | 2,068,000Source | 1,879,000Source | 1,821,000Source | 7,931,000Source | 6,826,000Source | 1,356,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 1,501,714Source |
| InterestExpenseNonoperatingUSD | — | — | 471,000Source | 264,000Source | — | 624,000Source | — | 495,000Source | 1,590,000Source | 816,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 6,125,038Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,482,000Source | -5,960,000Source | -5,982,000Source | -5,690,000Source | -4,351,000Source | -4,998,000Source | -23,756,000Source | -20,795,000Source | -29,908,000Source | 19,233,710Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,747,000Source | -7,340,000Source | -7,272,000Source | -6,942,000Source | -5,701,000Source | -6,236,000Source | -28,662,000Source | -27,973,000Source | -29,908,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -774,000Source | -988,000Source | -413,000Source | -620,000Source | 1,608,000Source | 109,000Source | -1,486,000Source | -1,539,000Source | -11,537,000Source | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 4,888,124Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,000Source | 13,000Source | 166,000Source | -1,000Source | 6,000Source | -11,000Source | -23,000Source | -26,000Source | 80,000Source | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 208,000Source | 233,000Source | 827,000Source | 916,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 29,997,000Source | — | 414,000Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | — | — | -13,332,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 42,000Source | 56,000Source | 51,000Source | 78,000Source | 39,000Source | 46,000Source | 241,000Source | 225,000Source | 316,000Source | — |
| Cost of RevenueUSD | — | — | 203,000Source | 187,000Source | 278,000Source | 234,000Source | 313,000Source | 226,000Source | 874,000Source | 742,000Source | 789,000Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 7,276,000Source | — |
| Operating Income (Loss)USD | — | — | -5,708,000Source | -4,972,000Source | -5,569,000Source | -5,070,000Source | -5,959,000Source | -5,107,000Source | -22,270,000Source | -19,256,000Source | -18,371,000Source | -4,888,124Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,000Source | 13,000Source | 166,000Source | -1,000Source | 6,000Source | -11,000Source | -23,000Source | -26,000Source | 80,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -23,756,000Source | — | — | 20,735,424Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 1,501,714Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,482,000Source | -5,960,000Source | -5,982,000Source | -5,690,000Source | -4,351,000Source | -4,998,000Source | -23,756,000Source | -20,795,000Source | -29,908,000Source | 19,233,710Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.35Source | -0.39Source | -0.07Source | -0.32Source | -0.08Source | -0.29Source | -1.23Source | -1.49Source | -2.38Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.35Source | -0.39Source | -0.07Source | -0.32Source | -0.08Source | -0.29Source | -1.23Source | -1.49Source | -2.38Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 21,851,606Source | 18,616,362Source | 104,039,109Source | 21,383,852Source | 68,934,960Source | 21,326,609Source | 23,259,598Source | 18,790,448Source | 12,552,925Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 21,851,606Source | 18,616,362Source | 104,039,109Source | 21,383,852Source | 68,934,960Source | 21,326,609Source | 23,259,598Source | 18,790,448Source | 12,552,925Source | — |
| Interest Expense (non-operating)USD | — | — | 471,000Source | 264,000Source | — | 624,000Source | — | 495,000Source | 1,590,000Source | 816,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Benefits, Losses and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| Costs and ExpensesUSD | — | — | 5,750,000Source | 5,028,000Source | 5,620,000Source | 5,148,000Source | 5,998,000Source | 5,153,000Source | 22,511,000Source | 19,481,000Source | 18,687,000Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | — | — | — | — | — | — | — | — | — | 103,000Source | -69,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,442,000Source | 1,690,000Source | 2,029,000Source | 2,068,000Source | 1,879,000Source | 1,821,000Source | 7,931,000Source | 6,826,000Source | 1,356,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -23,534,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | 624,000Source | — | 495,000Source | 1,590,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 6,125,038Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,747,000Source | -7,340,000Source | -7,272,000Source | -6,942,000Source | -5,701,000Source | -6,236,000Source | -28,662,000Source | -27,973,000Source | -29,908,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -774,000Source | -988,000Source | -413,000Source | -620,000Source | 1,608,000Source | 109,000Source | -1,486,000Source | -1,539,000Source | -11,537,000Source | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 4,888,124Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | 697,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 2,700,000Source | 2,757,000Source | 3,132,000Source | 2,485,000Source | 3,642,000Source | 2,748,000Source | 12,486,000Source | 10,179,000Source | 8,956,000Source | — |
| Selling and Marketing ExpenseUSD | — | — | 405,000Source | 394,000Source | 181,000Source | 361,000Source | 164,000Source | 358,000Source | 1,220,000Source | 1,734,000Source | 1,666,000Source | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | — | — | — | —Source | — | — | — | — | — | — | — | — |
Offerings
Registration 333-290927
Registration 333-292260
- Gross proceeds
- 29997294.62
- Net proceeds
- 27897294.62
- Deal price
- 0.4
- Shares
- 74993237
- Offering price
- $0.4000
Underwriters: H.C. Wainwright & Co., LLC
Registration 333-293369
- Gross proceeds
- 29997294.62
- Net proceeds
- 27897294.62
- Deal price
- 0.4
- Shares
- 74993237
- Offering price
- $0.4000
Underwriters: H.C. Wainwright & Co., LLC
Filing attachments
ea030969601ex99-1.htm · 8-K · 2026-10-27
Exhibit 99.1 Envoy Medical Announces Reverse Stock Split White Bear Lake, Minnesota - October 22, 2026 - Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock (“Common Stock”), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the “Reverse Split”). The Company’…
Read attachment ↗ea030137201ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ea030137201ex99-1.htm PRESS RELEASE DATED AUGUST 10, 2026 Exhibit 99.1 Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or th…
Read attachment ↗ea029652401ex99-1.htm · 8-K · 2026-06-30
EX-99.1 2 ea029652401ex99-1.htm PRESS RELEASED ISSUED BY THE COMPANY ON JUNE 24, 2026 Exhibit 99.1 Envoy Medical Terminates At-the-Market (ATM) Equity Facility Termination Reflects Company’s Confidence in Current Capital Position White Bear Lake, Minnesota, June 24, 2026 - Envoy Medical®, Inc. (NASDAQ: COCH) (“Envoy Medical”), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the “ATM F…
Read attachment ↗ea028996501ex99-1.htm · 8-K · 2026-05-11
EX-99.1 2 ea028996501ex99-1.htm PRESS RELEASE DATED MARCH 11, 2026 Exhibit 99.1 Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-Of-Its-Kind Fully Implanted Cochlear Implant Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota - May 11, 2026 - Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing …
Read attachment ↗ea028306501ex99-1.htm · 8-K · 2026-03-27
EX-99.1 2 ea028306501ex99-1.htm PRESS RELEASE DATED MARCH 23, 2026 Exhibit 99.1 Envoy Medical Reports Full Year 2025 Financial Results Received FDA approval to expand fully implanted Acclaim® Cochlear Implant Pivotal Clinical Trial to final stage Strengthened balance sheet by extinguishing $32 million in debt Subsequent to year-end, closed on transformational capital raise led by established institutional healthcare investors and completed enrollment of Pivotal Clinical Trial for first-o…
Read attachment ↗ea027697201ex99-1_envoy.htm · 8-K · 2026-02-13
Exhibit 99.1 Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering $30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cash Offering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company’s board of directors and management Net pr…
Read attachment ↗